Inclusion Criteria:  18 years or older and capable of signing their own consent form Scheduled for minimally invasive radical prostatectomy with pelvic lymph node dissection  Exclusion Criteria:  Prior pelvic surgery or pelvic radiation therapy Known central nervous or peripheral nervous system disease or insult (including neurodegenerative diseases), current use of neurotoxic medications, or use of cytotoxic chemotherapy with known neurotoxicity within 1 month Exposure to investigational agents in the immediate 30 days before or 15 days after study drug administration Patients with significant renal dysfunction (<60 mL/min as assessed by the Cockcroft Gault calculation for creatinine clearance) Exposure to phototoxic drugs such as St. John's wort, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones, and tetracyclines, should be avoided. If safe to discontinue use for at least 48 hours, patients may participate on this trial but will discontinue use for 24 hours before and after administration of Illuminare-1.